Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 2/3 1Phase 2 1

Status

Recruiting 4Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 2Lymphoid 1Breast 1

Conditions

Breast Neoplasms 3137Neoplasms 2474Carcinoma, Non-Small-Cell Lung 1883Prostatic Neoplasms 1641Colorectal Neoplasms 1432Lung Neoplasms 1308Multiple Myeloma 937Neoplasm Metastasis 926Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 860Ovarian Neoplasms 814Melanoma 791Carcinoma, Hepatocellular 743Stomach Neoplasms 647Recurrence 640Brain Neoplasms 640Squamous Cell Carcinoma of Head and Neck 638Head and Neck Neoplasms 609Glioblastoma 573Uterine Cervical Neoplasms 549Lymphoma 549Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 504Endometrial Neoplasms 467Hematologic Neoplasms 464Urinary Bladder Neoplasms 462Colonic Neoplasms 447Lymphoma, Non-Hodgkin 437Sarcoma 436

Interventions

pembrolizumab 1fludarabine 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × 1 year × Clear all
NCT06788990 2026-06-02

FORTIFI-HN01

Bicara Therapeutics

Phase 2/3 Recruiting
650 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT05209776 2026-06-01

LI-ARVC

University Hospital, Toulouse

Phase NA Recruiting
80 enrolled

Camurati-Engelmann Syndrome, Inflammation, Arrhythmogenic Right Ventricular Dysplasia

NCT05637216 2026-04-24

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Shaw Cancer Center

Phase 2 Recruiting
43 enrolled
Breast

Radiation Fibrosis Syndrome, Breast Neoplasms, Camurati-Engelmann Syndrome, Fibrosis, Inflammation

NCT06487624 2026-04-13

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

FBD Biologics Limited

Phase 1 Recruiting
50 enrolled
Lymphoid

Camurati-Engelmann Syndrome, Hodgkin Disease, Neoplasms

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Baylor College of Medicine

Phase 1 Active not recruiting
14 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡